Moderna, Inc. (MRNA)
Moderna's Newfound War Chest Opens Door for 4 Strategic Acquisition Targets
Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) acquisition currency just changed complexion.
Moderna, Coinbase, Strategy, Walmart, Alibaba, and More Stocks That Explain Today's Market
Moderna tumbles as investors take some profit following Wednesday's surge, while crypto stocks rally.
Wall Street Breakfast Podcast: Moderna's $44B Booster
Moderna (MRNA) soared 177% in a single day, driven by positive late-stage cancer vaccine results with Merck. Despite the rally, I maintain a Hold rating on MRNA, citing the need for full Phase 3 data and regulatory clarity.
Why Moderna Stock's Historic Surge Is a Big Lesson for Markets
Many Fed officials favor raising rates to combat inflation, bond prices surge, Trump meets crypto execs, and more news to start your day.
Opinion | Moderna's Road to a Cancer Vaccine
The company says a trial met its goal to prevent melanoma recurrence.
U.S. Stocks Gain as Treasury Buybacks Calm Bond Yields; Moderna Surges
U.S. stocks rose after the government said it would buy back more longer-dated bonds, easing pressure on a market that had pushed borrowing costs to their highest levels in nearly two decades.
Moderna Surges as Stocks Rise & Long-Term Yields Retreat | Closing Bell
Comprehensive cross-platform coverage of the U.S. market close on Bloomberg Television, Bloomberg Radio, and YouTube with Romaine Bostick, Isabelle Lee, Carol Massar and Emily Graffeo. -------- More on Bloomberg Television and Markets Like this video?
Tempus AI stock is soaring and it has Moderna to thank
Tempus AI (TEM) stock ripped higher on August 19 as third-party clinical breakthroughs triggered a technical short squeeze. As investors cheered TEM, it broke decisively above its major moving averages (MAs), indicating bulls have taken back control across multiple timeframes.
Moderna's Cancer Breakthrough Just Made Tempus AI's $1.5 Billion Bet Look Brilliant
$1.5 billion. That is what Tempus AI (NASDAQ:TEM | TEM Price Prediction) agreed to pay for Personalis (NASDAQ:PSNL) in a definitive merger announced July 20, 2026, a deal structured as a 100% stock transaction with a Tempus option to elect cash for up to half the consideration.
$1,000 invested in Moderna stock a week ago is now worth
As Moderna Inc. (NASDAQ: MRNA) stock spiked sharply on August 19, catalyzed by positive late-stage trial results for its personalized mRNA (messenger ribonucleic acid) cancer vaccine; $1,000 invested in this company a week ago has more than doubled in value.
From COVID to Cancer: Moderna Scores Melanoma Breakthrough
By successfully applying individualized mRNA technology to train the immune system against recurring tumor cells, Moderna and Merck have opened an extraordinary new frontier in targeted cancer treatment.
Merck Soars On Cancer Vaccine Trial Win With Moderna, More Upside Ahead
Merck & Co., Inc. surges to all-time highs after positive Phase 3 melanoma vaccine trial results with Moderna. MRK maintains a Buy rating, citing strong oncology growth, robust free cash flow, and technical breakout potential. Despite a GAAP loss from a strategic acquisition, MRK's forward-normalized profit path and capital allocation remain healthy.
